ELDISINE vindesine sulfate 5mg powder for injection vial

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

vindesine sulfate, Quantity: 5 mg

Commercializzato da:

Aspen Pharmacare Australia Pty Ltd

Forma farmaceutica:

Injection, powder for

Composizione:

Excipient Ingredients: mannitol

Via di somministrazione:

Intravenous

Confezione:

1 vial of powder 5mg

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code) ELDISINE is indicated in the palliative treatment of the following: Acute lymphocytic leukaemia of childhood resistant to other agents. Blastic crises of chronic myeloid leukaemia in adults. Non-small cell lung cancer. It should be noted that ELDISINE is usually given in combination with other oncolytic agents.

Dettagli prodotto:

Visual Identification: A white to off-white lyophilised plug; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

1997-08-14